SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia - PubMed (original) (raw)

Clinical Trial

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia

Anjali S Advani et al. Br J Haematol. 2014 Oct.

Abstract

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukaemia (AML) blasts to chemotherapy. A Phase 1 study demonstrated the safety of high dose pravastatin given with idarubicin and cytarabine in patients with AML and also demonstrated an encouraging response rate. The Southwestern Oncology Group (SWOG) trial, SWOG S0919, was a Phase 2 trial evaluating the complete remission (CR) rate in a larger number of patients with relapsed AML treated with idarubicin, cytarabine and pravastatin. This study closed to accrual after meeting the defined criterion for a positive study. Thirty-six patients with a median age of 59 years (range 23-78) were enrolled. The median time from diagnosis to registration was 18 months. Relapse status was first relapse, 17 patients (47%); second relapse, 15 patients (42%); third relapse, two patients (5·5%) and fourth relapse, two patients (5·5%). The response rate was 75% [95% confidence interval: 58-88%; 20 CRs, 7 CR with incomplete count recovery (CRi)], and the median overall survival was 12 months. The P-value comparing 75-30% (the null response rate based on prior SWOG experience) was 3·356 × 10(-4) . Given the encouraging CR/CRi rate, this regimen should be considered for testing in a prospective randomized trial against best conventional therapy.

Keywords: acute myeloid leukaemia; chemotherapy; cholesterol; pravastatin; relapse.

© 2014 John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

Disclosure/Conflicts of Interest

There are no conflicts of interest to disclose.

Similar articles

Cited by

References

    1. Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukaemia cells. Blood. 2004;104(6):1816–1824. - PubMed
    1. Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. European development of clofarabine as treatment for older patients with acute myeloid leukaemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010;28(14):2389–2395. - PubMed
    1. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman C, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz DR, Ohno R, Bloomfield CD. Revised recommendations of the Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia. Journal of Clinical Oncology. 2003;21:4642–4649. - PubMed
    1. Estey EH, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating H. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukaemia. Blood. 1996;88:756. - PubMed
    1. Estey EH, Thall PF, Cortes JE, Giles FJ, O’Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukaemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575–3583. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources